Affordably Source Imatinib (gleevec) For Cancer Experts and Industry Participants for Market Research, Diligence and Projects

Submit an anonymous Project Description -- Start receiving responses within a few hours

Have a need? Explain it here






How Zintro Works

  1. 1. Provide a clear description of your needs and your expectations of an expert, consultant or job candidate and Zintro will match it with the most relevant professionals in our platform.
  2. 2. Within a day or two typically 6 - 12 Experts, who have opted-in, will contact you with a brief explanation of their qualifications and how they can help.
  3. 3. You can communicate back and forth, qualify each other, connect and pay fees to Experts through Zintro.
  4. Zintro is free, anonymous and without obligation.

Loved by Thousands

Loved by thousands logos

Need Help?A phone icon1-877-236-7016

Recent Imatinib (gleevec) For Cancer Inquiries

Area Icon

Secondary-immunodeficiency In Blood Cancer

We would like to speak with physicians ( hematologist-oncologists, immunologists, and infectious disease specialists) involved in the diagnosis, treatment, and ongoing management of patients with sid that is associated with chronic lymphocytic leukemia (cll), multiple myeloma (mm), or non-hodgkin’s lymphoma (nhl). We are aiming to carry out message testing to identify messages that are most compelling to physicians with respect to the diagnosis and treatment of secondary immune deficiency (sid) associated with hematological cancers. This is a 75-minutes paid phone consultation and a 10 minutes pre-task. If open to participating, please provide a brief answer to the screener below: 1. Do you see at least 10 patients per month with secondary immunodeficiency (sid) associated with chronic lymphocytic leukemia (cll), multiple myeloma, or non-hodgkin’s lymphoma (nhl)? Please note that we are only interested in your personal point of view and are not seeking confidential information. Referrals are highly appreciated

  1. Profile Picture

    Mart |Marketing Director SPECT Europe

    Sorry no real *****, I'm not a physician and not in any way involved in ***** CLL. There...

    16 Hours Later
  2. Profile Picture

    VICTOR |Zintro Expert

    Thanks for asking for insights on this subject ***** confirm my availability for this consult...

    16.5 Hours Later
  3. Profile Picture

    Alessandro |Healthcare Manager

    I am not a physician but I have experience as biologist/***** payer....

    17.1 Hours Later
+6 Other Responses
Area Icon

Metastatic Pancreatic Cancer Market Access

We are looking for medical department chiefs or directors from the top pancreatic cancer treatment institutions in germany and france. We are interested in individuals who can provide insight on the market access landscape for current and future metastatic pancreatic cancer (pdac) therapies in germany and france. This is a paid 1-hour consultation for $300. Kindly respond with a brief answer as to your relevance in the space below: 1. Can you discuss the market access landscape metastatic pancreatic cancer (pdac) therapies in either germany and france?

  1. Profile Picture

    Arun |Senior Vice President Medical Affairs an

    Happy to discuss this as I have 19 years in this specific field. ...

    1.9 Days Later
  2. Profile Picture

    Mart |Marketing Director SPECT Europe

    My area of expertise is limited to the use of Nuclear Medicine theranostics in this disease. Nor rea...

    2.6 Days Later
  3. Profile Picture

    Christian |Clinical Trial Lead

    Yes, I can you discuss the market access landscape **********er (PDAC) therapies in ...

    3.3 Days Later
+20 Other Responses
Area Icon

Breast Cancer Care In China

I am looking for an expert on breast cancer care and imaging in china

  1. Profile Picture

    Richard |Theoretical Biologist

    I wrote: Gordon, R. (2011). Stop breast cancer now! Imagining imaging *****rds search, destr...

    8 Minutes Later
  2. Profile Picture

    Samir |Faculty

    Hello Margot, Thank you for your e-mail. I will be happy to provide with ***** these ...

    1 Day Later
+5 Other Responses
Area Icon

Targeted Small Molecules For Cancer Therapy

I am a theoretical biologist and clinical oncology researcher seeking an association with an established biotech/biopharmaceutical company for the development of a whole new class of targeted cancer drugs. The foundational work is conceptual but a provisional patent for drug development has been submitted. Can you assist in this matter? . . . .

  1. Profile Picture

    Ali |Higher Education Consultant

    I have expertise and ***** drug delivery. What type of help do you need? AMallakin...

    1.1 Hours Later
  2. Profile Picture

    Vishal |Research Scientist

    Dear User, I am interested in your offer as I've PhD & Post PhD experience of Oncology and t...

    12.6 Hours Later
  3. Profile Picture

    Olivier |CEO, CSO, R&D Director, Head of NCD

    CapEval Pharma is a company founded in 2010 by Dr. Olivier Loget and providing development, registra...

    18.5 Hours Later
+16 Other Responses
Area Icon

Cancer Cachexia And Its Treatment

Consultant type: oncologist focus market: us discussion points: - to understand the pathophysiology and prevalence of cachexia in various cancer types. What is the unmet need? - what is the current standard of care for cancer cachexia - moa of standard of care for cancer cachexia - get opinion on a novel moa for this indication to gauge adoption chances

  1. Profile Picture

    Kenneth |Medical Oncologist

    Happy to help your client as I have been involved in this area of supportive care for over thirty ye...

    2.3 Hours Later
  2. Profile Picture

    Taral |Medical Oncologist

    treat cancer ***** cachexia ...

    3.3 Hours Later
  3. Profile Picture

    Shou |Zintro Expert

    I shall be happy to help. I have 35 years experience of *****arch and 25 years of exper...

    4.1 Hours Later
+19 Other Responses
Area Icon

Metastatic Pancreatic Cancer Therapy Market

We are looking for participants who can speak on the market access landscape for current and future metastatic pancreatic cancer therapies in germany. We are interested to speak with the following: - current or former regional / local payer; former national payer / consultant - kol stakeholders: ludwig-maximilians-universitat (lmu) munchen; joint practice for interdisciplinary oncology and hematology, freiburg this is a 60-minutes paid phone interview and a 90-minutes paid phone interview. Please provide a brief answer as to your relevance to this space: for payers: 1. How would you describe your current role? 2. Have you participated in any market research studies in the past month regarding metastatic pancreatic cancer? For kol stakeholders: 1. What is your primary specialty? 2. Approximately how many metastatic pancreatic cancer patients do you consult and/or treat on a monthly basis? 3. Please score your level of expertise and insight on the metastatic pancreatic cancer space from 1 to 5, where 1 is low and 5 is high. Please briefly elaborate. 4. Please score your ability to discuss the impact of clinical evidence packages on regulatory approval, access, and reimbursement in your market from 1 to 5, where 1 is low and 5 is high. Please briefly elaborate. 5. Please score your ability to review product profiles and provide thoughts on data points that would be most relevant to shape decision-making in your market from 1 to 5, where 1 is low and 5 is high. Please briefly elaborate. 6. Have you ever advised national, regional, and/or local healthcare decision-making bodies in your market? Please briefly elaborate.

  1. Profile Picture

    Werner |Head of MSL Oncology

    Rate: $250 1. What is your primary specialty? a. Oncology - Pharmaceutical Industry 2. Approximat...

    18 Hours Later
  2. Profile Picture

    Volker |European Life Science Accelerator/Pharma

    Yes, I am interested. 1. How would you describe your current role? - Consultant Pharma & Biotech 2...

    1.2 Days Later
  3. Profile Picture

    Hartmut |Medical Leader Benefit Assessment Cancer

    1. What is your primary specialty? Ans: Medical Affairs and benefit assessment in the pharmaceutica...

    1.4 Days Later
+14 Other Responses
Area Icon

Prostate Cancer

Hi, i am currently conducting a study on prostate cancer in mexico. The key areas of study are as below: 1.What are the core men's health issues in mexico besides prostate cancer? 2.Share of oncology drug market 3.Treatment 4.Policies 5. Insurance framework etc. I am working on a tight deadline and would highly appreciate your early response. Best regards, rikita

  1. Profile Picture

    Rita |Principle

    Hi Ritika, I would be delighted to assist you on this project. Please let me know if you would like...

    10 Hours Later
  2. Profile Picture

    Jerrod |Owner, Managing Consultant

    Good afternoon, I am very *****t the health and well being of the Mexican people. I could...

    13.4 Hours Later
  3. Profile Picture

    Francinna |Director of Collections and Reimbursemen

    I can help you out with the various modalities used for the ***** *****er as well as ...

    18.1 Hours Later
+5 Other Responses
Area Icon

Emerging Technologies In Oncology

Our client is interested in speaking with oncology key opinion leaders to better understand the future changes in imaging procedures and care pathways or patient journey centric. Ideally, they are looking for leaders who can discuss the following technology segments: theranostics, personalized medicine (in-vitro diagnostics, genomics, proteomics, radiomics), and artificial intelligence. An incentive of $400 will be paid to participants for a 1-hour phone interview. Please provide a brief answer as to your relevance to the space below: do you work in the us or european healthcare setting where patients with cancers (oncology) are treated? Which best describes you? Physician (md) - medical oncologist physician (md) – surgical oncologist physician (md) – radiation oncologist clinical or organizational leadership - md (chief medical officer, chief innovation officer, cxo role) pathologist (md) certified physician assistant advanced practice registered nurse (nurse practitioner, clinical nurse specialist, etc.) registered nurse others (please specify) which of the following emerging technology areas are you familiar with in the context of oncology patient diagnostics and treatment? A. Theranostics – imaging-related area pairing diagnostic and therapeutic agents b. Artificial intelligence c. Personalized medicine (including in-vitro diagnostics, genomics, proteomics, radiomics) d. Diagnostic imaging - use of imaging modalities as part of patient diagnosis and care depending on cancer (e.G. Mri, ct, mammography, pet, spect, ixr, x-ray, ultrasound please discuss briefly the current or future perspective on theranostics, personalized medicine (in-vitro diagnostics, genomics, proteomics, radiomics), artificial intelligence areas in terms of pain points, realized market usage, and growth. *please note that we are only interested in your personal point of view and are not seeking confidential information. **referrals are highly appreciated

  1. Profile Picture

    Athanasios |Planning Officer at Department of Pharma

    I am interested in this position. I work on oncology landscape in European healthcare organization. ...

    14.4 Hours Later
  2. Profile Picture

    Alejandro D. |Vice President

    I am a medical oncologist (MD) with 21 years of experience. Most of my career has been in Clinical R...

    14.6 Hours Later
  3. Profile Picture

    Timothy |Director Of Research and Development

    I have over 20 years experience in oncology and previcion medicine, as well as immunooncology and th...

    14.7 Hours Later
+36 Other Responses
Area Icon

Norwegian Market In Bladder Cancer

We are looking for participants who can speak on the market access landscape for bladder cancer therapies in norway. We are interested to speak with the following: - heor expert payers - healthcare providers (hematologists/oncologists/urologists) this is a 60-minutes paid phone interview. Please provide a brief answer as to your relevance to this space: for heor expert payers: 1. Please rate your level of expertise on the following topics on a scale of 1-5, where 1 represents low expertise and 5 represents industry-leading expertise: - national, regional or local hta assessments - risk-benefit and heor calculations - economic modeling & clinical trial review - pricing and reimbursement of adjuvant treatments in oncology 2. Have you ever advised national, regional, and/or local healthcare decision-making bodies in your market? Please briefly elaborate for healthcare providers: 1. Please rate your level of expertise on the following topics on a scale of 1-5, where 1 represents low expertise and 5 represents industry-leading expertise: - national, regional or local hta assessments - clinical trial design and clinical endpoint evaluation - patient sub-group analysis and patient population definition - muscle-invasive bladder cancer therapy selection - adjuvant therapy selection 2. Have you ever directly advised national, regional, and/or local healthcare decision-making bodies in your market? Please briefly elaborate.

  1. Profile Picture

    Eivid |Managing Director

    Rate: $250 Yes, I can help. I have been working with HE&MA for 20 years. I quite frequently have su...

    5.6 Hours Later
  2. Profile Picture

    Jan |Oncologist, Researcher

    rate: $250 Oslo Area, Norway I might be interested. FOR HEALTHCARE PROVIDERS: Have experience all...

    17.6 Hours Later
  3. Profile Picture

    Markus |First line sales manager

    Sorry, i have only knowledge of the german pharma / healthcare market...

    7.4 Days Later
+7 Other Responses
Area Icon

Advanced Cancer Tests And Treatments As A Concierge Service

Venture capitalist thinking of investing in a company which provides information about advanced cancer tests and treatment and concierge services to consumers; high price/high value fee for service. Looking for experts to help me understand this space.

  1. Profile Picture

    Shiva Murthy |Director, Clinical research and Business

    Hi Thanks for contacting me. I am interested to discuss on this. Let us fix up time mutually conveni...

    1.5 Hours Later
  2. Profile Picture

    Scott |Director of Basic Urologic Research; Ass

    Hi AB, I would be happy to serve as a consultant, however I want to ensure that my area of expert...

    1.6 Hours Later
  3. Profile Picture

    Mark |Management Consultant

    I would like to explore further to see if I might be able to shed light in this space. I have 10 yea...

    1.7 Hours Later
+11 Other Responses
Area Icon

Breast Cancer

Looking for experts in market & sale of breast cancer drugs for stage 2

  1. Profile Picture

    Rita |Principle

    Dear Biot575Nsf , I have been in the oncology field for 0ver 20 years, and have marketed and sold ...

    6 Hours Later
  2. Profile Picture

    Joanne |CEO

    I would be happy to help you with this project....

    6 Hours Later
  3. Profile Picture

    Jagdish |Consultant

    PLEASE LET ME SEND ME DETAILED REQUIRMENT ON PROJECT , WE CAN DO THIS....

    47.1 Days Later
+3 Other Responses
Area Icon

Breast Cancer

The zintro blog needs you!i’m looking for your expert opinion on the news below and a written response that is one to three paragraphs long.Your response may be used in an article that i will write and post on the zintro site.You will be named in the article and a link to your profile will be included.Your contribution is voluntary(there is no direct payment involved,but you will get lots of traffic to your profile).If interested,please send me your response via znotes within the next few days. Uc irvine medical center is the first in usa to use the marginprobe system,which reduces by half the need to reoperate and cut out breast cancer cells missed during an initial lumpectomy.When the probe touches an excised lumpectomy specimen,radio-frequency signals are transmitted into the tissue and reflected back to the console,where they’re analyzed using a specialized algorithm to determine tissue status.Will this method reduce the need for repeat surgeries? This is a great marketing opportunity to get your name and opinion published on our blog.Here is a sample: http://blog.Zintro.Com/2012/01/16/keystone-xl-pipeline-pros-and-cons/ please include your full name,we will link it to your expert profile,getting you more presence on zintro.If you have any questions,please let me know. Thank you! idil kan

  1. Profile Picture

    Vaidyaraj |director

    How disease occurs according to ayurveda? The small illness like cold, cough, fever, pain, headache...

    2.7 Hours Later
  2. Profile Picture

    Rita |Principle

    When do you need this by? I am not able to provide until June 14th. Best regards, Rita...

    2.1 Days Later
+2 Other Responses
See More Inquiries

Imatinib is a drug used to treat certain types of cancer. It is currently marketed by Novartis as Gleevec (USA) or Glivec (Europe/Australia) as its mesylate salt, imatinib mesilate (INN). It was originally coded during development as CGP57148B or STI-571 (these terms are used in early preclinical publications). It is used in treating chronic myelogenous leukemia (CML), gastrointestinal stromal tumors (GISTs) and a number of other malignancies.

Top Imatinib (gleevec) For Cancer Experts

See More Experts
Share
LinkedInTwitterFacebookGoogle+